In addition, other mechanisms of PARPi resistance involve modifications of the drug target, i.e., PARP1 conformation change to avoid PARP1 trapping—a phenomenon mentioned previously caused by PARPi drugs, although at present this has only been reported in pre-clinical BRCA1 mutant cancer models (Pettitt et al., 2018). This evidence concerns the gene BRCA1 and cancer.